Novartis to acquire Anthos Therapeutics from Blackstone Life Sciences for $3.1bn.

Novartis, a multinational pharmaceutical corporation, agreed to acquire Anthos Therapeutics, a transformative, clinical-stage biopharmaceutical company, from Blackstone Life Sciences, a private investment platform, for $3.1bn. “We are proud to have launched and helped grow Anthos by acquiring the rights to abelacimab, assembling a world class team, designing the clinical plan and financing its development. We believe abelacimab has the potential to be a leader in the new class of Factor XI anticoagulants and are pleased to have Novartis as a committed partner to advance the development and commercialization of abelacimab as a potential treatment option for the millions of patients at risk of strokes. This transaction is an affirmation of Blackstone Life Sciences’ ownership investment strategy, where we seek to find innovative products and build companies around them to meet unmet patient needs,” Nicholas Galakatos, Blackstone Life Sciences Global Head.